Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $8.4500 (3.81%) ($7.9300 - $8.4700) on Mon. May. 6, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5% (three month average) | RSI | 62 | Latest Price | $8.4500(3.81%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) ARKK(57%) IWO(57%) | Factors Impacting TGTX price | TGTX will decline at least -2.5% in a week (0% probabilities). VXX(-16%) UUP(-11%) TLT(-9%) VIXM(-7%) IFRA(-6%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.5% (StdDev 5%) | Hourly BBV | 0 () | Intraday Trend | 6.3% | | | |
|
1 - 5 Day Possible Target | $3.63(-57.04%) | 5 Day Moving Average | $8.03(5.23%) | 10 Day Moving Average | $8.04(5.1%) | 20 Day Moving Average | $8.06(4.84%) | To recent high | -0.4% | To recent low | 62.8% | Market Cap | $1.07b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |